BR112017008840A2 - intensificador de inibidores do homólogo 2 de zeste - Google Patents

intensificador de inibidores do homólogo 2 de zeste

Info

Publication number
BR112017008840A2
BR112017008840A2 BR112017008840A BR112017008840A BR112017008840A2 BR 112017008840 A2 BR112017008840 A2 BR 112017008840A2 BR 112017008840 A BR112017008840 A BR 112017008840A BR 112017008840 A BR112017008840 A BR 112017008840A BR 112017008840 A2 BR112017008840 A2 BR 112017008840A2
Authority
BR
Brazil
Prior art keywords
enhancer
zeste homolog
inhibitor enhancer
inhibitor
zeste
Prior art date
Application number
BR112017008840A
Other languages
English (en)
Inventor
Allen Newlander Kenneth
David Knight Steven
Tian Xinrong
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of BR112017008840A2 publication Critical patent/BR112017008840A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/06—Peri-condensed systems

Abstract

resumo ?intensificador de inibidores do homólogo 2 de zeste? esta invenção se refere aos novos compostos, de acordo com a fórmula (i), que são inibidores do intensificador do homólogo 2 de zeste (ezh2), às composições farmacêuticas contendo os mesmos, aos processos para sua preparação e ao seu uso na terapia para o tratamento de cânceres. (i)
BR112017008840A 2014-10-28 2015-10-28 intensificador de inibidores do homólogo 2 de zeste BR112017008840A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462069438P 2014-10-28 2014-10-28
US201462075596P 2014-11-05 2014-11-05
PCT/EP2015/075009 WO2016066697A1 (en) 2014-10-28 2015-10-28 Enhancer of zeste homolog 2 inhibitors

Publications (1)

Publication Number Publication Date
BR112017008840A2 true BR112017008840A2 (pt) 2017-12-19

Family

ID=54360465

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008840A BR112017008840A2 (pt) 2014-10-28 2015-10-28 intensificador de inibidores do homólogo 2 de zeste

Country Status (11)

Country Link
US (1) US20170334891A1 (pt)
EP (1) EP3212639A1 (pt)
JP (1) JP6571180B2 (pt)
KR (1) KR20170068603A (pt)
CN (1) CN107148419A (pt)
AU (1) AU2015340614B2 (pt)
BR (1) BR112017008840A2 (pt)
CA (1) CA2965729A1 (pt)
MA (1) MA40848A (pt)
RU (1) RU2017118165A (pt)
WO (1) WO2016066697A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
AU2017260854B2 (en) 2016-05-05 2020-01-30 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US11311524B2 (en) 2017-01-19 2022-04-26 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018177993A1 (de) 2017-03-31 2018-10-04 Bayer Cropscience Aktiengesellschaft Pyrazole zur bekämpfung von arthropoden
KR102451529B1 (ko) 2018-01-31 2022-10-06 미라티 테라퓨틱스, 인크. Prc2 억제제
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
MX2022000933A (es) * 2019-07-24 2022-05-06 Constellation Pharmaceuticals Inc Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer.
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566327B1 (en) * 2010-05-07 2017-03-29 Glaxosmithkline LLC Indoles
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
CN104039956A (zh) * 2011-11-04 2014-09-10 葛兰素史密斯克莱知识产权（第2号）有限公司 治疗方法
AU2013216721B2 (en) * 2012-02-10 2017-09-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
SG11201508203TA (en) * 2013-04-30 2015-11-27 Glaxosmithkline Ip No 2 Ltd Enhancer of zeste homolog 2 inhibitors
US9556157B2 (en) * 2013-07-10 2017-01-31 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors

Also Published As

Publication number Publication date
RU2017118165A (ru) 2018-11-29
AU2015340614B2 (en) 2018-07-19
EP3212639A1 (en) 2017-09-06
AU2015340614A1 (en) 2017-05-18
JP6571180B2 (ja) 2019-09-04
US20170334891A1 (en) 2017-11-23
CA2965729A1 (en) 2016-05-06
CN107148419A (zh) 2017-09-08
JP2017532360A (ja) 2017-11-02
RU2017118165A3 (pt) 2018-12-10
KR20170068603A (ko) 2017-06-19
WO2016066697A1 (en) 2016-05-06
MA40848A (fr) 2021-05-05

Similar Documents

Publication Publication Date Title
BR112017008840A2 (pt) intensificador de inibidores do homólogo 2 de zeste
BR112015027527A2 (pt) intensificador de inibidores do homólogo zeste 2
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
CO2017011851A2 (es) Compuestos novedosos
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
DOP2017000109A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
BR112018072740A2 (pt) realçador de inibidores de homólogo 2 de zeste
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112016015449A8 (pt) compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
BR112016028037A2 (pt) Novos compostos
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
TR201907614T4 (tr) Fosfoinositid 3-kinaz ihnibitörleri olarak kromen türevleri.
CR20170513A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap).
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak
BR112019000603A2 (pt) composto, composição farmacêutica, método para o tratamento de doenças e uso do composto
BR112018010616A2 (pt) compostos inibidores seletivos de mmp-12
BR112018009646A2 (pt) compostos de glicolipídeo e seus usos no tratamento de tumores

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements